Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

Among the quarter’s highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable):

* Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
* Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
* Company-wide, gross margin increased $2.0 million or 17%.
* Operating expenses decreased 7%, or to 57% of revenues, from 63%.
* EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
* Net loss for the quarter was reduced 70%.

Enzo Clinical Labs ("Lab") benefited in the quarter from increased market share and service volume increases in connection with its being named a participating provider for Empire BlueCross BlueShield in the metropolitan New York area. Revenues increased to $12.4 million, compared to $11.1 million a year ago and $11.7 million in the July 2010 quarter, gains of 12% and 6%, respectively. The Lab has increasingly moved to position itself as a provider of molecular diagnostic and other higher-margin esoteric services. Gross margins improved $0.5 million and $1.1 million year over year and sequentially, respectively Uncollectible accounts receivables increased to $1.1 million, from $0.9 million a year ago, primarily due to a change in payer mix which is expected to normalize in the months ahead.

Enzo Life Sciences’ profitability for the quarter improved due to benefits from the plan instituted in July to integrate functions and rationalize workforce levels. Product and royalty and license fee revenues of $13.3 million in the fiscal 2011 first quarter, compared with $14.1 million a year ago, and $13.2 million in the preceding three months. Product revenues declined $0.6 million over the prior year period mainly due to planned reduction in lower margin distributed products.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Eastern Pennsylvania and New Jersey. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics.

*****************************************

Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

"We are very excited to be acquiring Rozetta-Cell Life Sciences," stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."

Completion of the merger is subject to customary closing conditions, including receipt by the parties of all necessary board and shareholder approvals and third party consents. There can be no assurance that these conditions will be met or that the merger will be completed.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).

*****************************************

John Hancock Income Securities Trust (NYSE:JHS) John Hancock Advisers, LLC, an investment adviser to John Hancock Closed-End Funds, announced that MFC Global Investment Management (U.S.), LLC changed its name to John Hancock Asset Management a division of Manulife Asset Management (US) LLC ("John Hancock Asset Management").

John Hancock Income Securities Trust is a closed ended fixed income mutual fund launched by John Hancock Funds, LLC. It is co-managed by John Hancock Asset Management and John Hancock Advisers, LLC. The fund invests in the fixed income markets of United States.

*****************************************

Gold Fields Ltd. (NYSE:GFI) quarterly results as well as results for the six months ending December 2010 will be released on Friday, 18 February 2011. Gold Fields has changed its financial year-end from end-June to end-December and guidance for the financial year ending December 2011 will also be provided on 18 February 2011.

Gold Fields Limited is one of the world's largest unhedged producers of gold with attributable production of 3.5 million gold equivalent ounces per annum from nine operating mines in South Africa, Ghana, Australia and Peru.

*****************************************

RailAmerica, Inc. (NYSE:RA) reported that its total freight carloads for the month ended December 31, 2010 were 71,209, up 4.0% from 68,445 in December 2009. These results include the Ottawa Valley Railway (OVRR) operation. The Company increased shipments in December 2010 in nine out of twelve commodity groups compared to December 2009. Much of the increase was due to shipments of Coal, Metallic Ores and Metals, and Non-Metallic Minerals and Products.

RailAmerica, Inc. engages in the ownership and operation of short line and regional freight railroads in North America. As of December 31, 2009, it operated a portfolio of 40 individual railroads with approximately 7,400 miles of track in 27 U.S. states and 3 Canadian provinces.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).